Navin K Chintala

Senior Research Assistant
Navin Chintala


MS, Biotechnology and Entrepreneurship, Polytechnic Institute of NYU, Brooklyn, NY


Grosser R, Cherkassky L, Chintala NK, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471-482.

Li X, Eguchi T, Aly RG, Chintala NK, Tan KS, Zauderer MG, Dembitzer FR, Beasley MB, Ghebrehiwet B, Adusumilli PS, Peerschke EB. Globular C1q receptor (gC1qR/p32/HABP1) is overexpressed in malignant pleural mesothelioma and is associated with increased survival in surgical patients treated with chemotherapy. Front Immunol. 2019;9:1042.

Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16-26.

Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol. 2018;51:103-10.

Dozier J, Chintala NK, Adusumilli PS. Immunotherapy for thoracic malignancies. Indian J Thorac Card. 2018;34:54-64.

Tano ZE, Chintala NK, Li X, Adusumilli PS. Novel immunotherapy clinical trials in malignant pleural mesothelioma. Ann Transl Med. 2017;5(11):245.